.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Optimizing Therapy for Hairy Cell Leukemia

EP. 1: Hairy Cell Leukemia: Incidence and Presentation

June 18th 2019

EP. 2: A Differential Diagnosis of Hairy Cell Leukemia

June 18th 2019

EP. 3: Approaches to Frontline Therapy in HCL

June 18th 2019

EP. 4: Monitoring Response & Initiating Second-Line Therapy in HCL

June 18th 2019

EP. 5: Anti-CD22 Therapy in HCL: Moxetumomab Pasudotox

June 18th 2019

EP. 6: Moxetumomab Pasudotox for HCL: Managing Side Effects

June 18th 2019

EP. 7: Hairy Cell Leukemia: Unmet Needs and Combination Strategies

June 18th 2019

EP. 8: Parting Advice on Hairy Cell Leukemia Management

June 18th 2019

EP. 9: First-Line Therapy Options in Hairy Cell Leukemia

June 18th 2019

EP. 10: Indicators Prompting Treatment of HCL

June 18th 2019

EP. 11: HCL Combination Therapy: Rituximab and Purine Analog

June 18th 2019

EP. 12: Concurrent vs Sequential Rituximab in HCL

June 18th 2019

EP. 13: The Role of MRD in Treatment of HCL

June 18th 2019

EP. 14: Treating Relapsed/Refractory or Progressive HCL

June 18th 2019

EP. 15: The Use of Splenectomy in HCL Treatment

June 18th 2019

EP. 16: BRAF/MEK Inhibition in HCL Management

June 18th 2019

EP. 17: Non-Chemotherapy Agents & Anti-CD22 in HCL Treatment

June 18th 2019

EP. 18: Moxetumomab Pasudotox in HCL

June 18th 2019

EP. 19: HCL Management: Recommendations and Advice

June 18th 2019